Contrary to a warning placed on labels for CART-T cancer therapies, use of these treatments does not appear to boost the odds for a secondary cancer later, a new study shows. Researchers at Memorial ...

Researchers were perplexed when the Food and Drug Administration announced it was investigating whether CAR-T therapy, one of the most effective treatments for blood cancers, could cause lymphoma.

Remove this text and use the embed button to add an image. Although still in early clinical trials, if successful, E-SYNC could one day become the first CAR-T therapy to treat the aggressive brain ...

BENGALURU: At a global cell therapy symposium in the city, oncologists said India offers CAR-T cell therapy at one-tenth the ...

— WU-CART-007 achieved 91% overall response rate in global Phase 1/2 trial, substantially outperforming current standard of care — — BLA filing targeted for 2027; therapy holds potential to be first ...

The 21-year-old woman was in agony. For five years, her own body had waged a violent war against her colon. She had ulcerative colitis, a chronic inflammatory bowel disease that left her digestive ...

A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...

CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Elouise Wrisper’s cancer journey began with persistent back pain. It was 2021, and the retired teacher, who was active in ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...